Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Amchara Health specialises in bringing a better approach to creating a personalised health solution tailored to a person's needs and goals. Its aim is to educate and empower people about better health choices. This residential retreat brand is developing three health & wellness applications: HealthHub360, MyAmchara, and Amchara360. In the first 12 months, the company will aim to achieve more than 100,000 downloads of the Healthhub360 application. With the proceeds, Amchara will be marketing the MyAmchara app and rebrand it. Furthermore, there will be an international development of the application to cater to Canada, Australia, and the USA.
days to go:
Expired
investment:
£167,619
The Gut Stuff is a proactive advocate for gut health, educating a substantial community and offering an innovative app in BETA that aims to bridge gaps in the gut health market. With a strong presence in physical products, workplace education, and media, they're positioned to redefine the gut health category and leverage diversified revenue streams for growth during their expansion into the digital realm.
days to go:
Expired
investment:
£321,662
Hitmarker is a proprietary job platform that covers the entire video game sector. It aims to be the leading job provider in the $159 billion video game industry. It has a database of 67,000 candidates and has posted 46,000 jobs from 4,500 companies in 77 countries. The company asserts that one million people have used Hitmarker 2.5 million times to post or look for jobs. Hitmarker has been covered by publications like Forbes, CNBC, and The FT. It has also onboarded 20 partners, including The University of California, RGF Executive Search, and the British Esports Association. The company will use the investment to build a global network of localised platforms in crucial territories and expand its addressable market.
days to go:
Expired
investment:
£521,283
Clim8 is a financial technology company that aims to move billions of pounds of investment into sectors such as clean energy, clean technology, sustainable food, smart mobility, and recycling. It is authorised by the Financial Conduct Authority (FCA). The company quotes United Nations data arguing that the World needs to invest $2.4 trillion every year into clean energy, from now until 2035, to meet climate change targets. Clim8 aims to capitalise on this objective. It launched its app on iOS and Android in private beta in October 2020 and then in the App Store in March 2021. It claims that its users have invested from £25 up to £97,000. The company has raised £5 million in venture capital to date, secured up to £2 million in airtime for equity from Channel 4 Ventures, and garnered a 4.8 star rating in the App Store, from a cumulative 100 reviews. The company will use the investment to accelerate user acquisition and launch new product offerings including pensions.
days to go:
Expired
investment:
£2,849,790
Monva is an FCA approved, customer-centric intelligent comparison platform for financial products and services. It combines Artificial Intelligence (AI), machine learning and smart technology to enable its customers to select the most accurate financial product they wish to buy or invest in. Monva is initially targeting the Credit Card market, which will be followed by Loans, Energy, and Communications, which already represents a potential £3 billion opportunity. The company is targeting 80% of the adults in the UK market that have either never switched a financial product or switched only once. With the investment, the company will build the platform to make it more user friendly, develop strategic partnerships, and recruit staff who specialise technology and marketing.
days to go:
Expired
investment:
£479,440
MGB Biopharma is tackling the worldwide threat of antimicrobial resistance. The company is in the process of clinical study and designing a new class of antibiotic. They are looking for investment to start phase 2 of the study with 70% being supported by a grant.
days to go:
Expired
investment:
£1,309,621
